BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood ...

(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET imaging ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older. The blood test, which ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease. The test--called the Lumipulse ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...